No Data
No Data
The controlling shareholder of Guanhao Biology (300238.SZ) pledges 14.65 million shares
Guanhao Biotech (300238.SZ) announced that the company recently received a notice from Guangdong Zhiguang Biotechnology Co., Ltd. (“Guangdong Zhiguang”), the controlling shareholder of the company, and learned that it will hold 14.65 million shares of the company (accounting for 5.52% of the company's total share capital) to register the pledge registration business.
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutica
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutical, Shuyu Pingmin, Changshan Pharmaceutical, and Dian Diagnosis fell more than 3%.
Guanhao Biology (300238.SZ): As of March 20, 2024, the total number of shareholders of the company was 31,042
Gelonghui March 21丨Guanhao Biotech (300238.SZ) said on the investor interactive platform that as of March 20, 2024, the total number of shareholders of the company was 31,042.
Guan Hao Biology (300238.SZ): No plans to participate in the brain-computer interface conference
Gelonghui March 12 丨 Guanhao Biology (300238.SZ) said on the investor interactive platform that the company has no plans to participate in the brain-computer interface conference yet.
Guanhao Biology (300238) 2023 Report Review: Benvermode is growing rapidly and new biomaterial products are being released rapidly
Incident: The company released its 2023 annual report, achieving operating income of 400 million yuan (+7.1%); net profit attributable to shareholders of listed companies was 0.3 billion yuan. Achieved revenue of 100 million yuan (+14.3%) in the fourth quarter of 2023;
Guanhao Biotech (300238.SZ): 2023 net profit of 31.058 million yuan reversed year-on-year losses
Gelonghui March 5 | Guanhao Biotech (300238.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 404 million yuan, an increase of 7.13% over the previous year; net profit attributable to shareholders of listed companies was 31.058 million yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 305.554 million yuan; and basic earnings per share were 0.12 yuan.
No Data